A Pilot Study of the Effects of Oral Administration of Zavesca(R) on Anti-rhGAA Immune Response in Subjects With Pompe Disease Receiving rhGAA Enzyme Replacement Therapy
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2018
Price : $35 *
At a glance
- Drugs Miglustat (Primary)
- Indications Glycogen storage disease type II; Hypersensitivity
- Focus Pharmacodynamics
- 23 Oct 2018 Status changed from withdrawn prior to enrolment to discontinued.
- 24 Sep 2018 Planned End Date changed from 1 Dec 2019 to 1 Jul 2018.
- 24 Sep 2018 Status has been changed to withdrawn prior to enrolment.